Aeolus to test efficacy of drug against radiation exposure

Aeolus Pharmaceuticals is set to test in primates the efficacy of AEOL 10150, a compound for treating lung damage caused by radiation exposure. The study also aims to create an animal model that can be reviewed by the FDA in approving a product for pulmonary acute radiation syndrome. The company submitted a white paper to the Biomedical Advanced Research and Development Authority to request funding to advance development of the drug candidate.

View Full Article in: (free registration) · United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY